 |
BioWorld-International-2002-06-12
TopoTarget Acquires Prolifix For Cash, Stock; Raises $15.3M
TopoTarget Acquires Prolifix For Cash, Stock; Raises $15.3M
Danish oncology firm TopoTarget A/S acquired UK cell cycle specialist Prolifix Ltd. in a combined cash and shares deal. The Copenhagen-based company also raised DKK120 million (US$15.3 million) in new funding, from HealthCap of Stockholm and BankInvest of Copenhagen. (BioWorld International)